UNSPSC 51313104: Homochlorcyclizine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H23ClN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N5MVC31W2N, chemically known as 1-(p-chloro-.alpha.-phenylbenzyl)hexahydro-4-methyl-1h-1, 4-diazepine, dihydrochloride but generally known as homochlorcyclizine, which bears US NIH Compound Identifier 3627. European Medicines Agency schedules Homochlorcyclizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08050MIG.

UNSPSC 51313104 Homochlorcyclizine is a Commodity code that in practice does not reflect the pharmaceutical products actually being procured under it by state and local governments. Recent solicitations tagged to this code show activity in naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products — none of which are homochlorcyclizine. The code appears to be a tagging mismatch in the underlying procurement databases rather than an active commodity classification for homochlorcyclizine itself. State and local buyers posting under this code are seeking emergency response supplies, prescription benefit program modernization, and bulk pharmaceutical distribution capacity through cooperative purchasing vehicles rather than a single active pharmaceutical ingredient.

The issuing bodies include a county health department (Seminole County, Florida), a state health and human services commission (Texas HHS Commission), and a multistate cooperative purchasing alliance (Minnesota MMCAP serving multiple states including Oregon). Recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due Jul 26, 2023), Texas HHS's Request for Information on direct-to-manufacturer prescription programs (posted Apr 3, 2026), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products across participating state and local facilities (due Mar 26, 2026). Geographic activity spans Florida, Texas, Minnesota, and Oregon. The code shows no meaningful recent activity aligned to its nominal commodity definition and does not represent a viable pursuit category for homochlorcyclizine suppliers.